{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-209103","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.419780+00:00","generated_at":"2026-06-11T18:50:13.814918+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biote Q2 revenue up 19% to $49.3M; FY2023 guidance narrowed to lower end","bullets":["Revenue $49.3M (+19.1% YoY) driven by procedure (+9.8%) and supplement (+52.8%) growth; gross margin 67.9% (+60 bps).","GAAP net loss $(13.1M) ($(0.25)/share) vs $(21.3M) ($(0.34)) prior year; adjusted EBITDA $14.5M (+10.6%).","FY2023 guidance lowered to lower end of range: revenue $190-200M, adjusted EBITDA $56-60M, citing moderate H2 pace.","Completed warrant exchange and secondary offering to enhance share liquidity; launched Men's Health division and trials for expanded wellness products."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-209103","json":"https://secwatch.observer/filing/0001193125-23-209103.json","markdown":"https://secwatch.observer/filing/0001193125-23-209103.md","text":"https://secwatch.observer/filing/0001193125-23-209103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523209103/0001193125-23-209103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523209103/d516871d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:50:13.814918+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2208d7ee58653339a8800a2269661ac931c04db6","claim":"biote Corp. reported the second quarter ended June 30, 2023 results: revenue $49.3 million, net income $(13.1) million, EPS $(0.25). Guidance reaffirmed.","evidence_excerpt":"for the second quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior year period) • Revenue of $49.3 million, a 19.1% increase • Gross profit margin of 67.9%, a 60-basis point increase • Net loss of $(13.1) million and GAAP loss per share of $(0.25), compared to a net loss of $(21.3)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312523209103/0001193125-23-209103-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$49.3 million"},{"label":"Net income","value":"$(13.1) million"},{"label":"EPS","value":"$(0.25)"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}